cisplatin,carboplatin,abraxane,durvalumab,tremelimumab,gemcitabine,pemetrexed
astrazeneca,pfizer
['poseidon']
 yes, it is on the 3-year presentation from asco last year. no difference for kras or stk11, nothing analyzed for keap1 due to the small number of patients. poseidon had a better job on that group, but this is all post-hoc.
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.